Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 4/2017

16.03.2017 | SSIEM 2016

Inherited disorders of transition metal metabolism: an update

verfasst von: Peter T. Clayton

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Elements with a biological role include six trace transition metals: manganese, iron, cobalt, copper, zinc and molybdenum. Transition metals participate in group transfer reactions such as glycosylation and phosphorylation and those that can transfer an electron by alternating between two redox states such as iron (3+/2+) and copper (2+/1+) are also very important in biological redox reactions including the reduction of molecular oxygen and the transport of oxygen. However, these trace metals are also potentially toxic, generating reactive oxygen species through Fenton chemistry. Recently, a role of trace metals in host defence (“nutritional immunity”) has been recognized. The host can deprive the pathogen of a trace metal or poison it with a toxic concentration. Disorders leading to low concentrations of a trace metal can often be treated by supplementing that metal; disorders leading to excessively high concentrations can often be treated with chelating agents such as penicillamine and disodium calcium edetate. This update will address: i) the manganese/zinc transporters (because two new treatable disorders were described in 2016 – SLC39A8 deficiency and SLC39A14 deficiency); ii) copper transporter disorders because we need to improve the treatment of patients with neurological symptoms due to Wilson’s disease; and iii) iron homeostasis because recent progress in research into the metabolism of iron and its regulation helps us better understand several inborn errors affecting these pathways.
Literatur
Zurück zum Zitat Ahting U, Mayr JA, Vanlander AV, Hardy SA, Santra S, Makowski C, Alston CL, Zimmermann FA, Abela L, Plecko B, Rohrbach M, Spranger S, Seneca S, Rolinski B, Hagendorff A, Hempel M, Sperl W, Meitinger T, Smet J, Taylor RW, Van Coster R, Freisinger P, Prokisch H, Haack TB (2015) Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency. Front Genet 6:123CrossRefPubMedPubMedCentral Ahting U, Mayr JA, Vanlander AV, Hardy SA, Santra S, Makowski C, Alston CL, Zimmermann FA, Abela L, Plecko B, Rohrbach M, Spranger S, Seneca S, Rolinski B, Hagendorff A, Hempel M, Sperl W, Meitinger T, Smet J, Taylor RW, Van Coster R, Freisinger P, Prokisch H, Haack TB (2015) Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency. Front Genet 6:123CrossRefPubMedPubMedCentral
Zurück zum Zitat Barupala DP, Dzul SP, Riggs-Gelasco PJ, Stemmler TL (2016) Synthesis, delivery and regulation of eukaryotic heme and Fe-S cluster cofactors. Arch Biochem Biophys 592:60–75CrossRefPubMedPubMedCentral Barupala DP, Dzul SP, Riggs-Gelasco PJ, Stemmler TL (2016) Synthesis, delivery and regulation of eukaryotic heme and Fe-S cluster cofactors. Arch Biochem Biophys 592:60–75CrossRefPubMedPubMedCentral
Zurück zum Zitat Boycott KM, Beaulieu CL, Kernohan KD, Gebril OH, Mhanni A, Chudley AE, Redl D, Qin W, Hampson S, Küry S, Tetreault M, Puffenberger EG, Scott JN, Bezieau S, Reis A, Uebe S, Schumacher J, Hegele RA, McLeod DR, Gálvez-Peralta M, Majewski J, Ramaekers VT, Care4Rare Canada Consortium, Nebert DW, Innes AM, Parboosingh JS, Abou Jamra R (2015) Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am J Hum Genet 97(6):886–893CrossRefPubMedPubMedCentral Boycott KM, Beaulieu CL, Kernohan KD, Gebril OH, Mhanni A, Chudley AE, Redl D, Qin W, Hampson S, Küry S, Tetreault M, Puffenberger EG, Scott JN, Bezieau S, Reis A, Uebe S, Schumacher J, Hegele RA, McLeod DR, Gálvez-Peralta M, Majewski J, Ramaekers VT, Care4Rare Canada Consortium, Nebert DW, Innes AM, Parboosingh JS, Abou Jamra R (2015) Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am J Hum Genet 97(6):886–893CrossRefPubMedPubMedCentral
Zurück zum Zitat Canonne-Hergaux F, Gruenheid S, Govoni G, Gros P (1999) The Nramp1 protein and its role in resistance to infection and macrophage function. Proc Assoc Am Physicians 111(4):283–289CrossRefPubMed Canonne-Hergaux F, Gruenheid S, Govoni G, Gros P (1999) The Nramp1 protein and its role in resistance to infection and macrophage function. Proc Assoc Am Physicians 111(4):283–289CrossRefPubMed
Zurück zum Zitat Chen P, Chakraborty S, Mukhopadhyay S, Lee E, Paoliello MM, Bowman AB, Aschner M (2015) Manganese homeostasis in the nervous system. J Neurochem 134(4):601–610CrossRefPubMedPubMedCentral Chen P, Chakraborty S, Mukhopadhyay S, Lee E, Paoliello MM, Bowman AB, Aschner M (2015) Manganese homeostasis in the nervous system. J Neurochem 134(4):601–610CrossRefPubMedPubMedCentral
Zurück zum Zitat Chesi G, Hegde RN, Iacobacci S, Concilli M, Parashuraman S, Festa BP, Polishchuk EV, Di Tullio G, Carissimo A, Montefusco S, Canetti D, Monti M, Amoresano A, Pucci P, van de Sluis B, Lutsenko S, Luini A, Polishchuk RS (2016) Identification of p38 MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants. Hepatology 63(6):1842–1859CrossRefPubMedPubMedCentral Chesi G, Hegde RN, Iacobacci S, Concilli M, Parashuraman S, Festa BP, Polishchuk EV, Di Tullio G, Carissimo A, Montefusco S, Canetti D, Monti M, Amoresano A, Pucci P, van de Sluis B, Lutsenko S, Luini A, Polishchuk RS (2016) Identification of p38 MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants. Hepatology 63(6):1842–1859CrossRefPubMedPubMedCentral
Zurück zum Zitat Chowanadisai W, Lönnerdal B, Kelleher SL (2006) Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency. J Biol Chem 281(51):39699–39707CrossRefPubMed Chowanadisai W, Lönnerdal B, Kelleher SL (2006) Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency. J Biol Chem 281(51):39699–39707CrossRefPubMed
Zurück zum Zitat Członkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M (2014) D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol 21(4):599–606CrossRefPubMed Członkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M (2014) D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol 21(4):599–606CrossRefPubMed
Zurück zum Zitat Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G (2005) Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 11(4):441–448CrossRefPubMed Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G (2005) Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 11(4):441–448CrossRefPubMed
Zurück zum Zitat Garringer HJ, Irimia JM, Li W, Goodwin CB, Richine B, Acton A, Chan RJ, Peacock M, Muhoberac BB, Ghetti B, Vidal R (2016) Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary ferritinopathy. PLoS One 11(8):e0161341CrossRefPubMedPubMedCentral Garringer HJ, Irimia JM, Li W, Goodwin CB, Richine B, Acton A, Chan RJ, Peacock M, Muhoberac BB, Ghetti B, Vidal R (2016) Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary ferritinopathy. PLoS One 11(8):e0161341CrossRefPubMedPubMedCentral
Zurück zum Zitat Kambe T, Tsuji T, Hashimoto A, Itsumura N (2015) The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. Physiol Rev 95(3):749–784CrossRefPubMed Kambe T, Tsuji T, Hashimoto A, Itsumura N (2015) The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. Physiol Rev 95(3):749–784CrossRefPubMed
Zurück zum Zitat Küry S, Dréno B, Bézieau S, Giraudet S, Kharfi M, Kamoun R, Moisan JP (2002) Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 31(3):239–240CrossRefPubMed Küry S, Dréno B, Bézieau S, Giraudet S, Kharfi M, Kamoun R, Moisan JP (2002) Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 31(3):239–240CrossRefPubMed
Zurück zum Zitat Lichtmannegger J, Leitzinger C, Wimmer R, Schmitt S, Schulz S, Kabiri Y, Eberhagen C, Rieder T, Janik D, Neff F, Straub BK, Schirmacher P, DiSpirito AA, Bandow N, Baral BS, Flatley A, Kremmer E, Denk G, Reiter FP, Hohenester S, Eckardt-Schupp F, Dencher NA, Adamski J, Sauer V, Niemietz C, Schmidt HH, Merle U, Gotthardt DN, Kroemer G, Weiss KH, Zischka H (2016) Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest 126(7):2721–2735CrossRefPubMedPubMedCentral Lichtmannegger J, Leitzinger C, Wimmer R, Schmitt S, Schulz S, Kabiri Y, Eberhagen C, Rieder T, Janik D, Neff F, Straub BK, Schirmacher P, DiSpirito AA, Bandow N, Baral BS, Flatley A, Kremmer E, Denk G, Reiter FP, Hohenester S, Eckardt-Schupp F, Dencher NA, Adamski J, Sauer V, Niemietz C, Schmidt HH, Merle U, Gotthardt DN, Kroemer G, Weiss KH, Zischka H (2016) Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest 126(7):2721–2735CrossRefPubMedPubMedCentral
Zurück zum Zitat Litwin T, Dzieżyc K, Karliński M, Chabik G, Czepiel W, Członkowska A (2015) Early neurological worsening in patients with Wilson’s disease. J Neurol Sci 355(1-2):162–167CrossRefPubMed Litwin T, Dzieżyc K, Karliński M, Chabik G, Czepiel W, Członkowska A (2015) Early neurological worsening in patients with Wilson’s disease. J Neurol Sci 355(1-2):162–167CrossRefPubMed
Zurück zum Zitat Martinelli D, Dionisi-Vici C (2014) AP1S1 defect causing MEDNIK syndrome: a new adaptinopathy associated with defective copper metabolism. Ann N Y Acad Sci 1314:55–63CrossRefPubMed Martinelli D, Dionisi-Vici C (2014) AP1S1 defect causing MEDNIK syndrome: a new adaptinopathy associated with defective copper metabolism. Ann N Y Acad Sci 1314:55–63CrossRefPubMed
Zurück zum Zitat Martinelli D, Travaglini L, Drouin CA, Ceballos-Picot I, Rizza T, Bertini E, Carrozzo R, Petrini S, de Lonlay P, El Hachem M, Hubert L, Montpetit A, Torre G, Dionisi-Vici C (2013) MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain 136:872–881CrossRefPubMed Martinelli D, Travaglini L, Drouin CA, Ceballos-Picot I, Rizza T, Bertini E, Carrozzo R, Petrini S, de Lonlay P, El Hachem M, Hubert L, Montpetit A, Torre G, Dionisi-Vici C (2013) MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain 136:872–881CrossRefPubMed
Zurück zum Zitat Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41(3):404–407CrossRefPubMed Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41(3):404–407CrossRefPubMed
Zurück zum Zitat Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC (2000) Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93(1):58–66CrossRefPubMed Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC (2000) Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93(1):58–66CrossRefPubMed
Zurück zum Zitat Niederau C1, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110(4):1107--19 Niederau C1, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110(4):1107--19
Zurück zum Zitat Park JH, Hogrebe M, Grüneberg M, DuChesne I, von der Heiden AL, Reunert J, Schlingmann KP, Boycott KM, Beaulieu CL, Mhanni AA, Innes AM, Hörtnagel K, Biskup S, Gleixner EM, Kurlemann G, Fiedler B, Omran H, Rutsch F, Wada Y, Tsiakas K, Santer R, Nebert DW, Rust S, Marquardt T (2015) SLC39A8 Deficiency: A Disorder of manganese transport and glycosylation. Am J Hum Genet 97(6):894--903 Park JH, Hogrebe M, Grüneberg M, DuChesne I, von der Heiden AL, Reunert J, Schlingmann KP, Boycott KM, Beaulieu CL, Mhanni AA, Innes AM, Hörtnagel K, Biskup S, Gleixner EM, Kurlemann G, Fiedler B, Omran H, Rutsch F, Wada Y, Tsiakas K, Santer R, Nebert DW, Rust S, Marquardt T (2015) SLC39A8 Deficiency: A Disorder of manganese transport and glycosylation. Am J Hum Genet 97(6):894--903
Zurück zum Zitat Park J H, Hogrebe M, Grueneberg M, Reunert J, Rust S, Marquardt T (2016) SLC39A8 deficiency is a novel treatable disorder of manganese metabolism and glycosylation. J Inherit Metab Dis 39(Issue 1 Supplement S54) Park J H, Hogrebe M, Grueneberg M, Reunert J, Rust S, Marquardt T (2016) SLC39A8 deficiency is a novel treatable disorder of manganese metabolism and glycosylation. J Inherit Metab Dis 39(Issue 1 Supplement S54)
Zurück zum Zitat Quadri M, Federico A, Zhao T, Breedveld GJ, Battisti C, Delnooz C, Severijnen LA, Di Toro Mammarella L, Mignarri A, Monti L, Sanna A, Lu P, Punzo F, Cossu G, Willemsen R, Rasi F, Oostra BA, van de Warrenburg BP, Bonifati V (2012) Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 90(3):467–477CrossRefPubMedPubMedCentral Quadri M, Federico A, Zhao T, Breedveld GJ, Battisti C, Delnooz C, Severijnen LA, Di Toro Mammarella L, Mignarri A, Monti L, Sanna A, Lu P, Punzo F, Cossu G, Willemsen R, Rasi F, Oostra BA, van de Warrenburg BP, Bonifati V (2012) Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 90(3):467–477CrossRefPubMedPubMedCentral
Zurück zum Zitat Rahman S, Mayr JA (2016) Disorders of oxidative phosphorylation. In: Saudubray JM et al (eds) Inborn metabolic diseases. Springer, Berlin Rahman S, Mayr JA (2016) Disorders of oxidative phosphorylation. In: Saudubray JM et al (eds) Inborn metabolic diseases. Springer, Berlin
Zurück zum Zitat Ramakrishnan B, Ramasamy V, Qasba PK (2006) Structural snapshots of beta-1,4-galactosyltransferase-I along the kinetic pathway.J. Mol Biol 357(5):1619–1633CrossRef Ramakrishnan B, Ramasamy V, Qasba PK (2006) Structural snapshots of beta-1,4-galactosyltransferase-I along the kinetic pathway.J. Mol Biol 357(5):1619–1633CrossRef
Zurück zum Zitat Riley LG, Cowley MJ, Gayevskiy V, Roscioli T, Thorburn DR, Prelog K, Bahlo M, Sue CM, Balasubramaniam S, Christodoulou J (2016) A SLC39A8 variant causes manganese deficiency, and glycosylation and mitochondrial disorders. J Inherit Metab Dis. doi:10.1007/s10545-016-0010-6 Riley LG, Cowley MJ, Gayevskiy V, Roscioli T, Thorburn DR, Prelog K, Bahlo M, Sue CM, Balasubramaniam S, Christodoulou J (2016) A SLC39A8 variant causes manganese deficiency, and glycosylation and mitochondrial disorders. J Inherit Metab Dis. doi:10.1007/s10545-016-0010-6
Zurück zum Zitat Schlaug G, Hefter H, Engelbrecht V, Kuwert T, Arnold S, Stöcklin G, Seitz RJ (1996) Neurological impairment and recovery in Wislon’s disease: evidence from PET and MRI. J Neurol Sci 136:129–139CrossRefPubMed Schlaug G, Hefter H, Engelbrecht V, Kuwert T, Arnold S, Stöcklin G, Seitz RJ (1996) Neurological impairment and recovery in Wislon’s disease: evidence from PET and MRI. J Neurol Sci 136:129–139CrossRefPubMed
Zurück zum Zitat Sharma V, Karlin KD, Wikström M (2013) Computational study of the activated O(H) state in the catalytic mechanism of cytochrome c oxidase. Proc Natl Acad Sci U S A 110(42):16844–16849CrossRefPubMedPubMedCentral Sharma V, Karlin KD, Wikström M (2013) Computational study of the activated O(H) state in the catalytic mechanism of cytochrome c oxidase. Proc Natl Acad Sci U S A 110(42):16844–16849CrossRefPubMedPubMedCentral
Zurück zum Zitat Tuschl K, Mills PB, Parsons H, Malone M, Fowler D, Bitner-Glindzicz M, Clayton PT (2008) Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia--a new metabolic disorder. J Inherit Metab Dis 31(2):151–163CrossRefPubMed Tuschl K, Mills PB, Parsons H, Malone M, Fowler D, Bitner-Glindzicz M, Clayton PT (2008) Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia--a new metabolic disorder. J Inherit Metab Dis 31(2):151–163CrossRefPubMed
Zurück zum Zitat Tuschl K, Clayton PT, Gospe SM Jr, Gulab S, Ibrahim S, Singhi P, Aulakh R, Ribeiro RT, Barsottini OG, Zaki MS, Del Rosario ML, Dyack S, Price V, Rideout A, Gordon K, Wevers RA, Chong WK, Mills PB (2012) Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 90(3):457–466CrossRefPubMedPubMedCentral Tuschl K, Clayton PT, Gospe SM Jr, Gulab S, Ibrahim S, Singhi P, Aulakh R, Ribeiro RT, Barsottini OG, Zaki MS, Del Rosario ML, Dyack S, Price V, Rideout A, Gordon K, Wevers RA, Chong WK, Mills PB (2012) Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 90(3):457–466CrossRefPubMedPubMedCentral
Zurück zum Zitat Tuschl K, Meyer E, Valdivia LE, Zhao N, Dadswell C, Abdul-Sada A, Hung CY, Simpson MA, Chong WK, Jacques TS, Woltjer RL, Eaton S, Gregory A, Sanford L, Kara E, Houlden H, Cuno SM, Prokisch H, Valletta L, Tiranti V, Younis R, Maher ER, Spencer J, Straatman-Iwanowska A, Gissen P, Selim LA, Pintos-Morell G, Coroleu-Lletget W, Mohammad SS, Yoganathan S, Dale RC, Thomas M, Rihel J, Bodamer OA, Enns CA, Hayflick SJ, Clayton PT, Mills PB, Kurian MA, Wilson SW (2016) Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun 7:11601CrossRefPubMedPubMedCentral Tuschl K, Meyer E, Valdivia LE, Zhao N, Dadswell C, Abdul-Sada A, Hung CY, Simpson MA, Chong WK, Jacques TS, Woltjer RL, Eaton S, Gregory A, Sanford L, Kara E, Houlden H, Cuno SM, Prokisch H, Valletta L, Tiranti V, Younis R, Maher ER, Spencer J, Straatman-Iwanowska A, Gissen P, Selim LA, Pintos-Morell G, Coroleu-Lletget W, Mohammad SS, Yoganathan S, Dale RC, Thomas M, Rihel J, Bodamer OA, Enns CA, Hayflick SJ, Clayton PT, Mills PB, Kurian MA, Wilson SW (2016) Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun 7:11601CrossRefPubMedPubMedCentral
Zurück zum Zitat van Hasselt PM, Clayton P, Houwen RHJ (2016) Disorders in the transport of copper, iron, magnesium, manganese, selenium and zinc. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn metabolic diseases. Diagnosis and treatment, 6th edn. Springer, Berlin van Hasselt PM, Clayton P, Houwen RHJ (2016) Disorders in the transport of copper, iron, magnesium, manganese, selenium and zinc. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn metabolic diseases. Diagnosis and treatment, 6th edn. Springer, Berlin
Zurück zum Zitat Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873CrossRefPubMed Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873CrossRefPubMed
Metadaten
Titel
Inherited disorders of transition metal metabolism: an update
verfasst von
Peter T. Clayton
Publikationsdatum
16.03.2017
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 4/2017
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0030-x

Weitere Artikel der Ausgabe 4/2017

Journal of Inherited Metabolic Disease 4/2017 Zur Ausgabe

Highlights

News and views

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.